Efficacy and safety of immune checkpoint blockade in self-identified Black patients with advanced non-small cell lung cancer.

ABSTRACT:

Background

To the authors' knowledge, race-based differences in efficacy for the treatment of patients with advanced non-small cell lung cancer (NSCLC) have not been studied to date due to the underrepresentation of patients of minority backgrounds in pivotal trials. In the current study, the authors examined real-world differences in outcome in a diverse patient population.

Methods

The authors retrospectively analyzed the clinical outcomes of patients with advanced NSCLC who were treated with single-agent immune checkpoint blockade (ICB) between 2013 and July 2018 at Winship Cancer Institute of Emory University in Atlanta, Georgia. Primary efficacy comparison between Black patients and White patients was performed using bivariate and multivariate analyses for overall surviv

SUBMITTER: Nazha B 

PROVIDER: S-EPMC7717500 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature